FDA lifts hold on RXi breast cancer vaccine trial
On September 12, 2011, RXi Pharmaceuticals Corporation announced a clinical trial update on its lead program, NeuVax , a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab .

FDA acts against Duluth firm selling dietary supplements
The company has agreed to change its marketing tactics.